Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly

References

• Melmed S. Acromegaly. N Engl J Med. 2006;355:2558–2573.
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102–152.
   PubMed Web of Science ®Google Scholar
• Rosario PW, Calsolari MR. Screening for acromegaly by application of a single questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary. 2012 Jun;15(2):179–183.
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–4775.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly–advances in diagnosis and treatment. Nat Rev Endocrinol. 2012 Oct;8(10):605–611.
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–1517.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526–529.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest. 2008;31:820–838.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al.; Acromegaly Consensus Group. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014 Apr;10(4):243–248.
   PubMed Web of Science ®Google Scholar
• Colao A, Martino E, Cappabianca P, et al. First-line therapy of acromegaly: a statement of the A.L.I.C. E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest. 2006;29:1017–1020.
   PubMed Web of Science ®Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152:379–387.
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest. 2014 Oct;37(10):1017–1030.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011 May;96(5):1327–1335.
   PubMed Web of Science ®Google Scholar
• Freda PU, Reyes CM, Nuruzzaman AT, et al. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitarytumors. Pituitary. 2004;7(1):21–30.
   PubMedGoogle Scholar
• Grasso LF, Pivonello R, Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):288–294.
   PubMed Web of Science ®Google Scholar
• Tutuncu Y, Berker D, Isik S, et al. Comparison of octreotide LAR and lanreotide Autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398–404.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235–247.
   Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014 May;99(5):1825–1833.
   PubMed Web of Science ®Google Scholar
• Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: an audit of performance from the UK National External Quality Assessment scheme. Horm Res. 1999;51(Suppl 1):13–19.
   PubMedGoogle Scholar
• Pokrajac A, Wark G, Ellis AR, et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007 Jul;67(1):65–70.
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR_ (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–868.
   PubMed Web of Science ®Google Scholar
• Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, openlabel, multicentre study. Clin Endocrinol (Oxf). 2009;70(5):757–768.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4):1397–1403.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Salgado LR. Bronstein MD treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 2005;63(2):168–175.
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151(3):317–324.
   PubMed Web of Science ®Google Scholar
• Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008;68(3):473–480.
   PubMed Web of Science ®Google Scholar
• Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–1050.
   PubMed Web of Science ®Google Scholar
• Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract. 2008;14(7):846–855.
   PubMedGoogle Scholar
• Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf). 2011;74(6):736–743.
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60(6):734–740.
   PubMed Web of Science ®Google Scholar
• Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014 Apr;99(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson-Chazot F, Kuhn J-M, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69(2):299–305.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf). 2009;71(2):237–245.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157(5):579–587.
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R. The Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf). 2006;65(3):320–326.
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel_ therapy: a randomized, placebocontrolled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18–28.
   PubMed Web of Science ®Google Scholar
• Oki Y, Inoue T, Imura M, et al. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study. Endocr J. 2009;56(9):1095–1101.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67(4):512–519.
   PubMed Web of Science ®Google Scholar
• Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115–122.
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Teramoto A, Hizuka N, et al. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013;60(5):651–663.
   PubMed Web of Science ®Google Scholar
• Ghigo E, Biller BM, Colao A, et al. Comparison of pegvisomant and longacting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924–933.
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM. Sheppard MC Efficacy of Sandostatin LAR (long-actingsomatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf). 2004;60(3):375–381.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. 2016;19(2):210–221.
   Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60–67.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112–2118.
   PubMed Web of Science ®Google Scholar
• Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405–4410.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011 Apr;32(2):247–271.
   PubMed Web of Science ®Google Scholar
• Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–1050.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007 Nov;157(5):579–587.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009 Aug;161(2):331–338. Epub 2009 May 22. doi:10.1530/EJE-09-0372.
   PubMed Web of Science ®Google Scholar
• Grasso LF, Pivonello R, Colao A. Investigational therapies for acromegaly. Expert Opin Investig Drugs. 2013 Aug;22(8):955–963.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al.; Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Nov;2(11):875–884.
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286(1–2):69–74.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al.; Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010 Jun;95(6):2781–2789.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707–716.
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab. 2004 Jun;89(6):3027–3032.
   PubMed Web of Science ®Google Scholar
• Bronstein MD, Fleseriu M, Neggers S, et al.; Pasireotide C2305 Study Group. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord. 2016 Apr 2;16(1):16.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154(3):467–477.
   PubMed Web of Science ®Google Scholar
• Colao A, Arnaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest. 2007;30(8):693–699.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res. 2011 Jun;21(3):129–133.
   PubMed Web of Science ®Google Scholar
• Higham CE, Chung TT, Lawrance J, et al. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf). 2009 Jul;71(1):86–91.
   PubMed Web of Science ®Google Scholar
• Jehle S, Reyes CM, Sundeen RE, et al. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab. 2005 Mar;90(3):1588–1593.
   PubMed Web of Science ®Google Scholar
• Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009 Jul;161(1):21–25.
   PubMed Web of Science ®Google Scholar
• Muhammad A, van der Lely AJ, O’Connor RD, et al. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy? Eur J Endocrinol. 2016 May;174(5):663–667.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20;342(16):1171–1177.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Muller AF, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001;86(2):478–481.
   Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012 May;97(5):1589–1597.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. 2015 Feb;48(1):334–341.
   PubMed Web of Science ®Google Scholar
• Trainer PJ. ACROSTUDY: the first5years. Eur J Endocrinol. 2009 Nov;161(Suppl 1):S19–24.
   PubMed Web of Science ®Google Scholar
• Sievers C, Baur DM, Schwanke A, et al. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary. 2015 Dec;18(6):916–923.
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Nagashima M, Hashigaki S, et al. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. Endocr J. 2016 Jan 20;63:337–347. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Drake WM, Parkinson C, Akker SA, et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol. 2001 Oct;145(4):451–456.
   PubMed Web of Science ®Google Scholar
• Parkinson C, Whatmore AJ, Yates AP, et al. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf). 2003 Aug;59(2):168–174.
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005 Oct;90(10):5684–5691.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptorantagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007 Feb;92(2):476–482.
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007 Jan;156(1):75–82.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009 Nov;161(Suppl 1):S3–S10.
   PubMed Web of Science ®Google Scholar
• Marazuela M, Lucas T, Alvarez-Escolá C, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol. 2009 Apr;160(4):535–542.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009 Oct;71(4):549–557.
   PubMed Web of Science ®Google Scholar
• Filopanti M, Olgiati L, Mantovani G, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab. 2012 Feb;97(2):E165–E172. doi:10.1210/jc.2011-1769.
   Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, De Martino Martino MC, et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol. 2012 Dec 10;168(1):15–22. doi:10.1530/EJE-12-0596.
   PubMed Web of Science ®Google Scholar
• Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from acrostudy. Endocr Pract. 2015 Mar;21(3):264–274.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007 Dec;92(12):4598–4601.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011 Mar;164(3):325–333. doi:10.1530/EJE-10-0867.
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005 May 7–13;365(9471):1644–1646.
   PubMed Web of Science ®Google Scholar
• Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005 Oct;90(10):5627–5631.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatinanalogs in acromegaly. J Clin Endocrinol Metab. 2014 Oct;99(10):3644–3652.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009 Oct;71(4):549–557.
   PubMed Web of Science ®Google Scholar
• Bianchi A, Valentini F, Iuorio R, et al. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res. 2013 Jun;21(32):40.
   Web of Science ®Google Scholar
• Roemmler J, Steffin B, Gutt B, et al. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res. 2010;20(5):338–344.
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola´ C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2013 Mar;16(1):101–108.
   PubMed Web of Science ®Google Scholar
• Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992 Sep;21(3):713–735.
   PubMed Web of Science ®Google Scholar
• Wass JA, Thorner MO, Morris DV, et al. Long-term treatment of acromegaly with bromocriptine. Br Med J. 1977 Apr 2;1(6065):875–878.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lombardi G, et al. Novel insights in dopamine receptor physiology. Eur J Endocrinol. 2007 Apr;156(Suppl 1):S13–S21.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab. 1986 Oct;63(4):941–945.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Paracchi A, Romano C, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 1988 Nov;29(5):467–476.
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997 Feb;82(2):518–523.
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998 Feb;83(2):374–378.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine. 2014 Jun;46(2):220–225.
   PubMed Web of Science ®Google Scholar
• Howlett TA, Willis D, Walker G, et al. UK Acromegaly Register Study Group (UKAR-3) control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013 Nov;79(5):689–699.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Lodrini S. Lasio G Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61:209–215.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology. 2009;90:82–92.
   PubMed Web of Science ®Google Scholar
• Mattar P, Alves Martins MR, Abucham J. Shortand long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology. 2010;92:120–127.
   PubMed Web of Science ®Google Scholar
• Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary. 2011;14:148–156.
   PubMed Web of Science ®Google Scholar
• Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60(4):507–515.
   PubMed Web of Science ®Google Scholar
• Gatta B, Hau DH, Catargi B, et al. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf). 2005;63:477–478.
   PubMed Web of Science ®Google Scholar
• Marazuela M, Ramos-Leví A, Sampedro-Núñez M, et al. Cabergoline treatment in acromegaly: pros. Endocrine. 2014 Jun;46(2):215–219.
   PubMed Web of Science ®Google Scholar
• Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90–98.
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699–1708.
   PubMed Web of Science ®Google Scholar
• Plöckinger U, Hoffmann U, Geese M, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012 Feb;166(2):223–234.
   PubMed Web of Science ®Google Scholar
• Trainer P, Newell-Price J, Ayuk L, et al. A Phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF-I in patients with acromegaly [abstract OR09-1]. Presented at the Endocrine Society’s 97th Annual Meeting and Exposition; ECE 2015, Dublin (Irland).
   Google Scholar